Based on this performance, the stock will get rocked. No reason to pay more than it traded for one year ago... $2.00. The market currently values MSON as a growth company, which it used to be. Two quarters in a row of declining revenues will exact a heavy toll on long investors.
Too severe. The big guys will understand the model. Can't see them letting it get too low. There isn't a lot of stock out there for sale. It's disappointing on the revenue side for sure but the company is cash flow poistive, has 6.1 milion in cash and has a model that will work and is working although more slowly then anyone wants. Probably loose a point or a point and a half but won't see 2 bucks. There are 42 bone scalpels out there. When it get's to 500 that alone will be $15,000,000 in revenue.